Future Cell Bio
Mirae Cell is a bio company specializing in evaluating the efficacy of innovative medicines and dementia drugs.
We are developing mesenchymal stem cells (MMSCs) derived from allogeneic embryonic stem cells to treat interstitial cystitis, and are also developing various pipelines.We develop and produce the world’s first six-fold transformation dementia cloned pig that simultaneously expresses the APP, TAU, and PS1 genes.We supply pharmaceutical raw materials with mesenchymal stem cells MMSC derived from allogeneic embryonic stem cells.
Mirae Cell Bio announced that it has obtained a Japanese patent for the production technology of mesenchymal stem cells derived from allogeneic embryonic stem cells.
Park Se-pil, a professor of biomedical information at Jeju National University, will transfer the world’s first dementia cloned pig production technology to Mirae Cell Bio.Mirae Cell Bio has announced that it will transfer “U.S. patent technology related to the production of pigs with dementia replicated by all three human dementia-causing genes (App, PS1, and Tau)” from Jeju National University.
[Stock Information]
Source: Save
http://www.datanet.co.kr/news/articleView.html?idxno=171870Future Cell Bio: “Help Develop New Dementia Drugs” following the transfer of U.S. patented technology – DatanetBion is an investment company, Mirae Cell Bio (CEO Kim Eun-young and Jung Hyun-min), which introduced a U.S. patent technology (US10,306,873B2) related to the production of dementia cloned pigs that express all three human dementia genes (APP, PS1, Tau) from Jeju National University…www.datanet.co.krhttps://www.edaily.co.kr/news/read?newsId=01971286632295792&mediaCodeNo=257&OutLnkChk=Yhttps://www.edaily.co.kr/news/read?newsId=01971286632295792&mediaCodeNo=257&OutLnkChk=Y